Welcome, Guest. Please login or register.
May 28, 2022, 04:36:00 pm

Login with username, password and session length


  • Total Posts: 335
  • Total Topics: 191
  • Online Today: 19
  • Online Ever: 518
  • (January 21, 2020, 05:24:49 pm)
Users Online
Users: 0
Guests: 13
Total: 13


Welcome to the Cancer Health Forums, a round-the-clock discussion area for people who have any type of cancer, their friends and family and others with questions about living with cancer. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Cancer Health Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Keytruda Beats Chemotherapy for Most Common Type of Advanced Lung Cancer  (Read 2013 times)

Offline Cancer Health Editors

  • Jr. Member
  • **
  • Posts: 56
    • View Profile
The immune checkpoint inhibitor Keytruda (pembrolizumab) led to longer survival than platinum-based chemotherapy for advanced non-small-cell lung cancer (NSCLC) patients with a PD-L1 level of 1 percent or higher, according to a study presented at the American Society of Clinical Oncology (ASCO) annual meeting this month in Chicago.

“A large number of patients with lung cancer now have a new treatment option withbetter efficacy and fewer side effects than standard chemotherapy,” said lead researcher Gilberto Lopes, MD, of the University of Miami’s Sylvester Comprehensive Cancer Center. “Our study shows that pembrolizumab provides more benefit than chemotherapy for two thirds of all people with the most common type of lung cancer.”



© 2022 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.